Amanote Research
Register
Sign In
Proteomics-Based Strategy to Identify Biomarkers and Pharmacological Targets in MLL/AF4 Leukemia
doi 10.1021/pr060235v.s001
Full Text
Open PDF
Abstract
Available in
full text
Date
Unknown
Authors
Unknown
Publisher
American Chemical Society (ACS)
Related search
circRNA circAF4 Functions as an Oncogene to Regulate MLL-AF4 Fusion Protein Expression and Inhibit MLL Leukemia Progression
Journal of Hematology and Oncology
Cancer Research
Oncology
Hematology
Molecular Biology
MLL-AF4 Spreading Identifies Binding Sites That Are Distinct From Super-Enhancers and That Govern Sensitivity to DOT1L Inhibition in Leukemia
Cell Reports
Biochemistry
Genetics
Molecular Biology
Proteomics Approaches to Identify Tumor Antigen Directed Autoantibodies as Cancer Biomarkers
Disease Markers
Biochemistry
Medicine
Clinical Biochemistry
Molecular Biology
Genetics
Proteasome Inhibitors Evoke Latent Tumor Suppression Programs in Pro-B MLL Leukemias Through MLL-AF4
Cancer Cell
Cancer Research
Oncology
Cell Biology
Comparing Proteomics and RISC Immunoprecipitations to Identify Targets of Epstein-Barr Viral miRNAs
PLoS ONE
Multidisciplinary
AF5q31, a Newly Identified AF4-related Gene, Is Fused to MLL in Infant Acute Lymphoblastic Leukemia With Ins(5;11)(q31;q13q23)
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Paradoxical Effects of MLL Paralogs in MLL-Rearranged Leukemia
Cancer Cell
Cancer Research
Oncology
Cell Biology
The Therapeutic Response and Clinical Outcome of Adults With ALL1(MLL)/AF4 Fusion Positive Acute Lymphoblastic Leukemia According to the GIMEMA Experience
Haematologica
Hematology
A Mouse Model Reveals Lineage Plasticity in MLL–AF4 Pro-B ALL
Cancer Discovery
Oncology
